Sinusitis diagnostics

About 20% of all prescribed antibiotics relate to sinusitis.
75% is predicted to be over-prescription.

New tool for sinus diagnostics is needed

Sinusitis is a common and painful disease. About 20% of all prescribed antibiotics globally relate to sinusitis. Of this, it is predicted that 75% is prescribed even though the condition is caused by virus. There is a great need to easily and accurately make a correct diagnosis when patients experience problems with their sinuses, already at the primary care centers. The current methods are often inaccurate or require expensive resources.

Our solution

The paranasal sinuses are cavities within the scull, which are ventilated through the nose. With GPX Medical technology it is possible to easily measure the amount of gas and the gas composition inside the sinus and gain clinically important information already at the primary care centers.

The method is easy and quick and the result is presented without delay. As the technique does not involve ionizing radiation of the sinuses in the skull it is very safe for the patient. It also means that the healthcare sector can reduce costly and time-consuming investigations as well as decrease prescription of antibiotics.

The feasibility of the technology has been shown in a clinical pilot study where the correlation between assessment of the openness of the sinuses based on CT scan and the GASMAS* method was shown**. The market opportunity for a diagnostic tool for sinusitis is currently under investigation.


*gas in scattering media absorption spectroscopy (GASMAS)

**Non-invasive diagnostics of the maxillary and frontal sinuses based on diode laser gas spectroscopy. Lewander M, Lindberg S, Svensson T, Siemund R, Svanberg K, Svanberg S. Rhinology. 2012 Mar;50(1):26-32.

For Investors

GPX Medical is on a journey to create better care for for our most vulnerable patients.

About GPX Medical

GPX Medical AB was formed in 2016 as a subsidiary to Gasporox AB (publ) with the aim to develop and commercialize medical applications of the GASMAS technology. The company is owned by Gasporox AB (publ) to 53,3%, by Norsk Elektro Optikk AS to 36,2% and by the team to 10,5%. The company is located in Lund, Sweden. Org. nbr. 559069-9012.

For investors

Please contact CEO Hanna Sjöström for investment opportunities:


GPX Medical AB
Tellusgatan 13
224 57 Lund